Ruth Collins, MSN, CRNP, OCN
Ultima Vez Modificado: 29 de septiembre del 2002
Dear OncoLink "Ask The Experts,"
My brother in law's last radiation treatment was 2 weeks ago. He still has pain and trouble swallowing. I believe the term is acute esophagitis. Can you tell me how long this lasts after radiation treatment is stopped?
Ruth Collins, MSN, CRNP, OCN, Advanced Practice Nurse in the Research Division of the Department of Radiation Oncology, responds:
When radiation therapy is the only treatment being used, esophagitis, usually has its onset at about 20-30 Gy, or two to three weeks into treatment. The condition usually begins to subside 10 days to 2 weeks post radiation. This is best accomplished if the person's nutritional status is maintained at an optimal level. If chemotherapy is being administered at the same time as the radiation, the esophagitis can take longer to subside. Immunocompromised patients with persistent symptoms should be should be assessed for potential infections such as esophageal candida.
Symptom regression can further be delayed by: acid reflux; poor nutritional status, foods strongly spiced or seasoned, dry coarse foods, hot foods and fluids, citrus or acidic or citrus food or juices; alcohol; smoking; medications such as aspirin or nonsteroidal anti-inflammatory medications or steroids.
Treatment for esopagitis consists of:
A clinical guide to cancer nursing: A companion to cancer nursing, 3rd. ed. Groenwald, S.L., Frogge, M.H., Goodman, M. & Yarboro, C.H. (Eds). Boston:Jones and Bartlett Publishers; 1995; pp.75, 246-47.
Kelvin, J.F. Gastrointestinal cancers In: Nursing care in radiation oncology, 2nd ed. Dow, K.H., Bucholtz, J.D., Iwamoto, R., Fieler, V. & Hilderley, L. (Eds). Philadelphia:W.B. Saunders Co.; 1997; p174.
Peacock, J L., Keller, J. W. & Asbury, R.F. Alimentary cancer In: Clinical oncology, 7th ed. Rubin, P. (Ed). Philadelphia:W.B. Saunders Co. 1993. p562-63.
Shank, B. Radiotherapy: Implications for general patient care In: Manual of oncologic therapeutics, 3rd ed. Macdonald. J. S., Haller, D. G. & Mayer, R. J.(Eds) Philadelphia:J.B. Lippincott; 1995; p.74.
Dec 7, 2010 - Rituximab may be a better option than watchful waiting in some lymphoma patients, and a new treatment option appears effective for relapsed or refractory Hodgkin's lymphoma, according to two studies being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. Other research being presented will highlight new options for the standard treatment of advanced asymptomatic follicular lymphoma; mantle cell lymphoma; and early, unfavorable Hodgkin's disease.
Jun 17, 2011
Jan 7, 2014